今日观察！A Wave of "Kete Valuation" Sweeps Through the Market: 50 Stocks Poised for Strong Growth

A Wave of "Kete Valuation" Sweeps Through the Market: 50 Stocks Poised for Strong Growth

Shanghai, China - June 17, 2024 - A recent surge in investor sentiment towards growth stocks, particularly in the healthcare and technology sectors, has been dubbed the "Kete Valuation" phenomenon, named after the Chinese pharmaceutical company C-Bridge (6160.HK). This trend is reminiscent of the "CATL Valuation" rally that occurred in 2021, driven by the strong performance of Contemporary Amperex Technology Co., Ltd. (300015.SZ).

The "Kete Valuation" is characterized by a sharp increase in the share prices of companies with promising growth prospects, often defying broader market trends. This is evident in the recent performance of 50 stocks identified by analysts as having significant growth potential. These stocks, spanning various industries including healthcare, technology, and consumer goods, have exhibited remarkable resilience amidst recent market volatility.

Factors Driving the "Kete Valuation"

Several factors are contributing to the "Kete Valuation" trend. Firstly, investors are increasingly seeking out companies that can deliver sustainable growth, particularly in the face of global economic uncertainties. Secondly, the easing of monetary policy in major economies is providing a supportive backdrop for riskier assets like growth stocks. Additionally, advancements in technology and innovation are creating new opportunities for companies in various sectors, fueling investor optimism.

Key Beneficiaries of the "Kete Valuation"

Among the 50 stocks identified as potential beneficiaries of the "Kete Valuation," C-Bridge (6160.HK) stands out as a frontrunner. The company's innovative cancer therapies and strong pipeline of new drugs have attracted significant investor interest. Other notable stocks include:

• Ascletis Pharma (1672.HK): A clinical-stage biopharmaceutical company developing novel therapies for cancer and viral diseases.

• Aier Eye Hospital Group (300015.SZ): A leading provider of comprehensive eye care services in China.

• Xiaomi Corporation (1810.HK): A global technology company known for its smartphones, smart home devices, and internet services.

Investment Implications

The "Kete Valuation" presents an opportunity for investors to capitalize on the growth potential of select companies. However, careful due diligence is crucial, as not all growth stocks are created equal. Investors should thoroughly evaluate a company's financial health, competitive landscape, and long-term growth prospects before making investment decisions.

The "Kete Valuation" highlights the evolving dynamics of the Chinese stock market, where investors are increasingly discerning and seeking out companies with genuine growth potential. This trend is likely to continue as China's economy transitions towards a more innovation-driven and knowledge-based model.

原创标题：AI生成图片引发版权争议：360被指“盗图”，周鸿祎被索赔1元

北京，2024年6月18日 - 近日，国内互联网安全公司360在新品发布会上展示的AI图片生成功能，引发了关于AI生成图片版权归属的巨大争议。一位名为“DynamicWang”的创作者指控360侵犯其版权，并向周鸿祎本人索赔1元。

事件起因于6月6日举行的360AI新品发布会暨开发者沟通会上。会上，360展示了其全新360AI搜索及360AI浏览器，其中一项功能可以对图片进行局部重绘。在演示过程中，360工作人员选取了两张女性图片，并输入了“性感”指令，生成了一张新的图片。

DynamicWang称，360所展示的图片，是其通过训练、调试的AI绘图模型生成的原图，经过重绘后生成的。他表示，自己并未授权360使用该图片，且360的行为构成侵权。

6月13日，DynamicWang在微博上发布了维权声明，并表示已向法院提起诉讼，要求360停止侵权并赔偿损失。他还表示，之所以只索赔1元，是为了维护自身权益，并推动AI版权问题的解决。

360方面则回应称，DynamicWang所指控的侵权行为并不成立。360表示，其AI图片生成功能是基于大量公开图片训练而成，并使用了原创的算法进行加工，不构成侵权。

这一事件引发了业界对AI生成图片版权归属的广泛讨论。一些专家认为，AI生成图片的版权应归属于AI开发者，但也有人认为，版权应归属于提供原始素材的用户。

目前，该事件仍在进一步发酵中。有法律人士表示，此案的判决结果将对AI生成图片的版权问题产生重大影响。

以下是对事件的几点扩充：

• DynamicWang是一位AI艺术创作者，他创作的图片曾在多个平台上展出和售卖。
• 360的AI图片生成功能仍在测试阶段，尚未正式上线。
• 一些网友认为，360应该为AI生成图片的版权问题制定更清晰的规则。

以下是该事件的几点启示：

• AI技术的发展，对传统版权概念提出了新的挑战。
• 在使用AI技术进行创作时，应注意版权问题。
• 有关部门应尽快完善相关法律法规，规范AI技术的应用。